SOLV · Solventum Corp
$90.93
-0.60 (-0.66%)
At close · Aug 27
Market Cap
$15.58B
Shares
170.22M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$8.33B
+0.9%
FY2025
Net Income
$1.56B
+224.8%
FY2025
Gross Margin
53.47%
-2.2pp
FY2025
Operating Margin
26.2%
+13.6pp
FY2025
Diluted EPS
$8.88
+221.7%
FY2025
Operating Cash Flow
$369M
-68.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| — | $8.31B | $8.33B | $8.25B | $8.2B | $8.13B | |
| — | $625M | $615M | $600M | $616M | $603M | |
| — | $4.55B | $4.45B | $4.59B | $4.69B | $4.7B | |
| — | — | 53.47% | 55.65% | 57.25% | 57.75% | |
| — | $724M | $739M | $775M | $758M | $767M | |
| — | $3.29B | $3.08B | $2.78B | $2.3B | $2.24B | |
| — | $333M | $312M | $349M | $365M | $373M | |
| — | — | $489M | $555M | $561M | $578M | |
| — | — | — | $62M | — | — | |
| — | $2.08B | $2.18B | $1.04B | $1.69B | $1.69B | |
| — | — | 26.2% | 12.55% | 20.64% | 20.82% | |
| — | — | $2.67B | $1.59B | $2.25B | $2.27B | |
| — | -$33M | -$39M | -$64M | -$25M | -$1M | |
| — | $1.7B | $1.71B | $605M | $1.67B | $1.69B | |
| — | $261M | $157M | $127M | $321M | $349M | |
| — | $1.43B | $1.56B | $479M | $1.35B | $1.34B | |
| — | — | 18.69% | 5.8% | 16.42% | 16.52% | |
| — | $1.4B | $1.99B | $291M | $1.47B | $1.05B | |
| USD/shares | — | $8.23 | $8.94 | $2.77 | $7.79 | $7.78 |
| USD/shares | $7.10 – $7.20* | $8.19 | $8.88G | $2.76 | $7.79 | $7.78 |
| shares | — | — | 174.1M | 173.2M | 172.7M | 172.7M |
| shares | — | — | 175.3M | 173.7M | 172.7M | 172.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.44×
Peer median 3.30×
EV/EBIT
9.75×
Peer median 33.60×
P/E (TTM)
11.18×
Peer median 39.50×
Peer medians compare against the 22 similar-size Medical Instruments & Supplies companies (of 45 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Med Surg Segment | $4,817,000,000 | $4,637,000,000 | $4,632,000,000 | $4,585,000,000 |
| Health Information Systems Segment | $1,360,000,000 | $1,306,000,000 | $1,285,000,000 | $1,227,000,000 |
| Dental Solutions Segment | $1,349,000,000 | $1,295,000,000 | $1,329,000,000 | $1,327,000,000 |
| Purification and Filtration Segment | $497,000,000 | $709,000,000 | $689,000,000 | $991,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| United States | $4,668,000,000 | $4,559,000,000 | $4,471,000,000 | $4,450,000,000 |
| Non Us | $3,657,000,000 | $3,695,000,000 | $3,726,000,000 | $3,680,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Product | $6,349,000,000 | $6,348,000,000 | $6,296,000,000 | $6,300,000,000 |
| Cost of Software and Rentals | $1,976,000,000 | $1,906,000,000 | $1,901,000,000 | $1,830,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Med Surg Segment | $810,000,000 | $887,000,000 | $1,107,000,000 | $1,061,000,000 |
| Health Information Systems Segment | $496,000,000 | $431,000,000 | $423,000,000 | $359,000,000 |
| Dental Solutions Segment | $346,000,000 | $350,000,000 | $442,000,000 | $437,000,000 |
| Purification and Filtration Segment | $96,000,000 | $74,000,000 | $111,000,000 | $177,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Med Surg Segment | 16.8% | 19.1% | 23.9% | 23.1% |
| Health Information Systems Segment | 36.5% | 33% | 32.9% | 29.3% |
| Dental Solutions Segment | 25.6% | 27% | 33.3% | 32.9% |
| Purification and Filtration Segment | 19.3% | 10.4% | 16.1% | 17.9% |
Key facts
CIK
1964738
CUSIP
83444M101
13F (30d)
621 filings
612 filers
Visit website
Investor relations